It’s January, which is typically when many of us are looking into shedding some pounds. We’ve been hearing a lot about how weight loss drugs are impacting weight loss. Dr. Joseph St. Pierre with Hartford HealthCare Digestive Health Institute joined Good Morning Connecticut at 9 a.

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on Medicaid and have become yo-yo dieters who, despite their best efforts at changing their eating habits and lifestyles,

The U.S. FDA has released a new draft guidance for drugmakers to aid them in developing new treatments for obesity. The new document replaces an earlier draft guidance issued in February 2007. The new guidance stated that its focus is on the design of clinical trials and endpoints to demonstrate sustained weight loss,

Losing weight by dieting (restricting energy) includes, along with fat loss, losing lean mass, about half of which is typically muscle. The general rule is that three-quarters of what we lose is fat and the rest is lean tissue.

What does the latest science say about the use of GLP-1 meds to treat obesity in people without diabetes?A review of 26 randomized, controlled trials concludes

According to that study, those who use GLP-1 dugs, such as Wegovy and Ozempic, cut their grocery spend by about 6% during the first few months after starting their prescription, translating to $416 annually. The impact is even greater in higher-income households earning over $125,000, who reduce their grocery spending by 9%, or $690, annually.

Study finds GLP-1 medications such as Ozempic could result in cuts to grocery spending and reductions in spending at fast-food restaurants

McGill University researchers say their study has found GLP-1 drugs are safe and effective for treating obesity and overweight adults without diabetes. The authors say the findings support using the medication to treat those who are overweight and obese among otherwise healthy patients.